Exelixis, Inc.
EXEL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000939767
No open-market purchases or sales by Exelixis, Inc. insiders were filed in the last 90 days; 762 institutions reported holding it in 13F filings for Q2 2026, worth $14.1B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 30, 2026, 1:15 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Jan 2, 2026 | Jan 3, 2025 | Dec 29, 2023 | Dec 30, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Revenue | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B |
| Cost of revenue | $83.7M | $76.2M | $72.5M | $57.9M | $52.9M |
| Research and development | $825.0M | $910.4M | $1.04B | $891.8M | $693.7M |
| Selling, general and administrative | $518.7M | $492.1M | $542.7M | $459.9M | $401.7M |
| Operating income | $872.2M | $604.6M | $170.9M | $201.5M | $286.7M |
| Income tax | $158.6M | $160.4M | $49.8M | $52.1M | $63.1M |
| Net income | $782.6M | $521.3M | $207.8M | $182.3M | $231.1M |
| EPS, basic | $2.88 | $1.80 | $0.65 | $0.57 | $0.73 |
| EPS, diluted | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 |
| Weighted shares, basic | 271.6M | 290.0M | 318.2M | 321.5M | 314.9M |
| Weighted shares, diluted | 281.9M | 296.1M | 321.5M | 324.6M | 322.4M |
| Margins and growth | |||||
| Operating margin | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% |
| Net margin | 33.7% | 24.0% | 11.4% | 11.3% | 16.1% |
| Revenue growth, year over year | +7.0% | +18.5% | +13.6% | +12.3% | +45.3% |
| Net income growth, year over year | +50.1% | +150.9% | +14.0% | −21.1% | +106.7% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Jan 2, 2026 | Jan 3, 2025 | Dec 29, 2023 | Dec 30, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Cash and equivalents | $482.5M | $217.4M | $263.0M | $501.2M | $647.2M |
| Short-term investments | $576.6M | $893.9M | $732.3M | $807.3M | $819.9M |
| Accounts receivable | $286.9M | $265.4M | $237.4M | $214.8M | $282.6M |
| Inventory | $21.7M | $22.4M | $17.3M | $33.3M | $27.5M |
| Total current assets | $1.44B | $1.47B | $1.32B | $1.62B | $1.83B |
| Property, plant and equipment | $99.0M | $119.4M | $128.7M | $110.6M | $104.0M |
| Goodwill | $63.7M | $63.7M | $63.7M | $63.7M | $63.7M |
| Total assets | $2.84B | $2.95B | $2.94B | $3.07B | $2.62B |
| Accounts payable | $29.6M | $38.2M | $33.8M | $32.7M | $24.3M |
| Total current liabilities | $405.6M | $403.8M | $394.3M | $324.4M | $337.6M |
| Total liabilities | $683.1M | $703.5M | $678.4M | $583.1M | $405.6M |
| Shareholders' equity | $2.16B | $2.24B | $2.26B | $2.49B | $2.21B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Jan 2, 2026 | Jan 3, 2025 | Dec 29, 2023 | Dec 30, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Operating cash flow | $884.3M | $700.0M | $333.3M | $362.6M | $400.8M |
| Capital expenditures | $8.43M | $28.4M | $40.5M | $27.7M | $64.2M |
| Free cash flow | $875.8M | $671.5M | $292.9M | $334.9M | $336.6M |
| Depreciation and amortization | $29.1M | $28.8M | $25.7M | $20.9M | $13.6M |
| Stock-based compensation | $113.0M | $93.8M | $106.3M | $107.6M | $119.8M |
| Share buybacks | $947.5M | $652.0M | $550.4M | – | – |
| Investing cash flow | $350.4M | -$116.8M | -$27.0M | -$524.4M | -$42.9M |
| Financing cash flow | -$969.6M | -$628.8M | -$546.1M | $586.0K | -$14.8M |
| Net change in cash | $265.1M | -$45.6M | -$239.7M | -$161.2M | $343.1M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 4.9% | 4.3% | 5.8% | 6.7% | 8.4% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 19, 2026 | 244.0M | −9.0% | SEC |
| Jul 27, 2026 | 247.8M | −8.0% | SEC |
| Apr 27, 2026 | 251.4M | −7.8% | SEC |
| Feb 2, 2026 | 259.7M | −7.2% | SEC |
| Oct 27, 2025 | 268.1M | −6.1% | SEC |
| Jul 21, 2025 | 269.2M | −5.6% | SEC |
| May 5, 2025 | 272.7M | −6.4% | SEC |
| Feb 3, 2025 | 279.9M | −7.7% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.